Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.

Scientific reports - 8 Apr 2015

Feng Chenchen, Sun Yang, Ding Guanxiong, Wu Zhong, Jiang Haowen, Wang Lujia, Ding Qiang, Wen Hui

Abstract excerpt

We aimed to exploit novel compounds with high selectivity to clear cell renal cell carcinoma (ccRCC) with common mutations. Using the GDSC databases, we searched for compounds with high selectivity for ccRCC with VHL and/or SETD2 mutations. Clinical impact and gene interactions were analysed using TCGA database. In vitro and in vivo studies were performed to validate the inhibitory effects of the compound. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone-Lysine N-Methyltransferase

Share to Morpholines

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Pyrimidinones

Share to Receptor, Notch1

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 25853938
DOI: 10.1038/srep09465
PMCID: PMC5396071

Genes

SETD2
VHL
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.PMID 25853938Read ↗

High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.Semantic proximity Read ↗

Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.Semantic proximity Read ↗

Significance of PTEN Mutation in Cellular Process, Prognosis, and Drug Selection in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibitionSemantic proximity Read ↗

POLR2A Drives Tumor Cell Aggressive in Both VHL and PBRM1 Mutation Renal-Cell CarcinomaSemantic proximity Read ↗

Frequent gene mutations and the correlations with clinicopathological features in clear cell renal cell carcinoma: preliminary study based on Chinese population and TCGA database.Semantic proximity Read ↗

Neuropilin 1 and Neuropilin 2 Gene Invalidation or Pharmacological Inhibition Reveals Their Relevance for the Treatment of Metastatic Renal Cell CarcinomaSemantic proximity Read ↗

Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma.Semantic proximity Read ↗

Exploiting Synthetic Lethal Network for Precision Treatment of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.Semantic proximity Read ↗

Combined Gene Expression Profiling and RNAi Screening in Clear Cell Renal Cell Carcinoma Identify PLK1 and Other Therapeutic Kinase TargetsSemantic proximity Read ↗

SETD2 deficiency impairs β-catenin destruction complex to facilitate renal cell carcinoma formationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.